Active Biotech AB: Notice of Extraordinary General Meeting of Shareholders

The Board of Directors of Active Biotech AB (publ) has issued a notice to an Extraordinary General Meeting, which is to take place at 5 p.m. on Monday, December 1, 2014, at 5 pm at the Company's premises at Scheelevägen 22 in Lund, Sweden.

Please see the attached notice, which is being announced in Svenska Dagbladet and published in Post- och Inrikes Tidningar within short.

Lund, November 5, 2014
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS

About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit www.activebiotech.com for more information.

Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Swedish Securities Market Act to make the information in this press release public. The information was submitted for publication at 08:32 a.m. CET on November 5, 2014.